

HIGH-GROWTH DIAGNOSTIC TESTING MARKETS *(SAMPLE COPY, NOT FOR RESALE)*

Trends, Industry Participants, Product Overviews and Market Drivers

TABLE OF CONTENTS

1.	Overview	11
1.1	Statement of Report	11
1.2	Scope of This Report	12
1.3	Methodology	13
1.4	Executive Summary	14
2.	Introduction to the High-Growth Testing Market	23
2.1	Introduction to the Global Diagnostic Market	23
2.2	General Areas with Potential for High-Growth Testing	24
2.3	Market Drivers in the High-Growth Diagnostics Testing Sector	26
2.4	Market Segments for High-Growth Testing	26
2.5	Key Players in the High-Growth Diagnostics Testing Segment	26
2.6	High-Growth Testing Sector Analysis	28
3.	Hepatitis Serologic Markers and Nucleic Acid Testing	29
3.1	Hepatitis B Virus (HBV)	29
3.2	Major Suppliers of Hepatitis B Virus (HBV) Testing Products	36
3.3	Market Revenue Analysis	39
3.4	Hepatitis C Virus (HCV) Testing	40
3.5	Market Revenue Analysis	48
4.	Human Papillomavirus (HPV) Testing	50
4.1	Overview	50
4.2	The Association of HPV and Cervical Cancer	52
4.3	The PAP Test	54
4.4	Current Laboratory Methods for HPV Detection	54
4.4.1	Direct-probe Methods	54
4.4.2	Signal Amplification	54
4.4.3	Target Amplification	54
4.5	Assays for HPV	55
4.6	Market Revenue Analysis	58
4.7	Competitor Activity	58
5.	HIV	61
5.1	Introduction to HIV/AIDS	61
5.2	Statistical Data Global HIV/AIDS Epidemic	61
5.3	HIV Prevention and Treatment	62
5.3.1	HIV Prevention	62
5.3.2	HIV Treatment	62
5.4	U.S. Testing Market	63
5.5	Market Dynamics	65
5.5.1	Market Drivers	65
5.5.2	Market Restraints	66
5.5.3	Market Trends	67
5.5.4	Technology Trends	69
5.6	Review of Selected HIV Testing Devices	69
5.7	Market Revenue Analysis	72
5.8	Competitor Activity	73
5.9	HIV Market Challenges and Strategic Recommendations	75
5.10	Insurance Coverage and Reimbursement	76
5.11	Policies Affecting HIV Testing	76
5.12	Recent Industry Activity	77

6.	Infectious Disease Testing	79	
6.1	Introduction to Infectious Disease Testing		79
6.2	Types of Diagnosis for Infectious Diseases		80
6.2.1	Microbial Culture	80	
6.2.2	Microscopy	80	
6.2.3	Biochemical Tests	80	
6.2.4	Molecular Diagnostics	80	
6.3	Diagnostic Platforms for Infectious Diseases		81
6.3.1	Centralized Laboratory Testing for Infectious Diseases		81
6.3.2	POC Testing for Infectious Diseases	81	
6.4	Emerging Technologies	82	
6.5	Qualitative Analysis	82	
6.5.1	Market Drivers	82	
6.5.2	Market Restraints	83	
6.6	Streptococcus Testing	83	
6.7	Chlamydia Testing	88	
6.8	Mononucleosis	89	
6.9	Gonorrhea	91	
6.10	Influenza	93	
6.11	Malaria	95	
6.12	Tuberculosis	104	
6.13	Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA)		112
6.14	Market Revenue Analysis	115	
7.	Cardiac Markers	116	
7.1	Market Overview	116	
7.2	Cardiac Marker Tests	116	
7.2.1	Creatine Kinase (CK)	116	
7.2.2	Myoglobin	117	
7.2.3	Cardiac Troponins T (TnT), I (TnI) and C (TnC)		117
7.2.4	C-Reactive Protein (CRP)	117	
7.2.5	Homocysteine	118	
7.3	Emerging Markers	118	
7.3.1	B-type Natriuretic Peptide (BNP)		118
7.3.2	Myeloperoxidase (MPO)	118	
7.3.3	Ischemia Modified Albumin (IMA)		119
7.3.4	Glycogen Phosphorylase Isoenzyme BB (GPBB)		119
7.3.5	Fatty Acid-Binding Proteins (FABPs)		119
7.4	Qualitative Analysis	120	
7.4.1	Market Drivers	120	
7.4.2	Market Restraints	121	
7.5	Specific Cardiac Conditions	121	
7.5.1	Acute Myocardial Infarction	121	
7.5.2	Heart Failure (BNP)	123	
7.5.2.1	Market Overview	123	
7.5.2.2	Commercial Assays for BNP and NT-proBNP		124
7.5.2.3	Clinical Applications of BNP	125	
7.5.3	CRP	128	
7.6	Pulmonary Embolism (D-dimer Test)		129
7.7	Key Players	130	
7.8	Market Revenue Analysis	137	
8.	Cytogenetic Testing	139	
8.1	Cancer Testing	140	
8.2	Prenatal Testing and Cytogenetics		142

8.2.1	Cystic Fibrosis Testing	143	
8.2.1.1	CF Testing Methodology	144	
8.2.1.2	CF Screening Technology Summary	147	
8.3	Key Players in Segment	148	
9.	Fertility Testing	149	
10.	Cancer Biomarker Testing	153	
10.1	Segment Overview	153	
10.2	The Cancer Testing Market	154	
10.3	Competition	156	
10.4	Individual Markets	156	
10.4.1	Cancer Pathology: Testing	156	
10.4.1.1	Rare Cell/Micro Metastasis Detection	157	
10.4.1.2	Cancer Pathology: High-Throughput Screening	158	
10.4.1.3	Competition	159	
10.4.1.4	Drivers	160	
10.4.2	Breast Cancer	160	
10.4.2.1	CA 15-3	161	
10.4.2.2	CA 27-29	161	
10.4.2.3	BRCA1 and BRCA2 Breast and Ovarian Cancer Genes	162	
10.4.2.4	Estrogen and Progesterone Receptor (ER and PR)	164	
10.4.2.5	HER-2	164	
10.4.2.6	Herceptin	165	
10.4.2.7	p53	165	
10.4.2.8	NMP66	165	
10.4.2.9	Mammastatin	166	
10.4.2.10	Drivers for Breast Cancer Test Development	166	
10.4.3	Ovarian Cancer	167	
10.4.3.1	Cancer Antigen 125 (CA125)	167	
10.4.3.2	BRCA1 and BRCA2	168	
10.4.3.3	Steroid Hormone Receptors	169	
10.4.3.4	Epidermal Growth Factor Receptor (EGFR)	169	
10.4.3.5	Lysophospholipids	171	
10.4.4	Cervical Cancer	171	
10.4.4.1	Cervical Cancer Screening Tests	172	
10.4.5	Colon Cancer DNA Testing	173	
10.5	Pharmacogenomic Cancer Testing	175	
10.6	Market Revenue Analysis	178	
11.	Substance Abuse Testing	180	
11.1	Background to POC Substance Abuse Testing	180	
11.2	Substance Abuse Test Types	187	
11.2.1	Urine Substance/Drug Screening	187	
11.2.2	Hair Tests for Substance Abuse and Screening	187	
11.2.3	Blood Tests for Substance Abuse and Screening	188	
11.2.4	Saliva Tests for Substance Abuse and Screening	188	
11.2.5	Sweat Tests for Substance Abuse and Screening	188	
11.3	Alcohol Abuse and Screening	188	
11.4	Saliva Testing	189	
11.5	Qualitative Analysis	189	
11.5.1	Market Drivers	189	
11.5.2	Market Restraints	190	
11.6	Review of Selected POC Substance Abuse Analyzers	190	
11.7	Review of Company Products	192	

11.7.1	Alere	192	
11.7.2	Abbott Diagnostics	192	
11.7.3	Roche Diagnostics	193	
11.7.4	BioScan Screening Systems, Inc.	194	
11.7.5	American Bio Medica Corp.	194	
11.7.6	Phamatech, Inc.	197	
11.7.7	First Check Medical	198	
11.7.8	OraSure	198	
11.7.9	Avitar, Inc.	199	
11.7.10	Concateno	199	
11.7.11	Pathtech	199	
11.7.12	Alfa Scientific Designs, Inc.	200	
11.7.13	TCPI, Inc.	201	
11.7.14	Roche	201	
11.7.15	Biophor Diagnostics	201	
11.7.16	Randox Laboratories	201	
11.7.17	Branan Medical	201	
11.7.18	Concateno	202	
11.6	Market Revenue Analysis	203	
12.	Vitamin D Diagnostic Testing	204	
12.1	Market Revenue Analysis	208	
13.	Renal Dialysis Testing	209	
14.	Companion Diagnostics	210	
14.1	Market Revenue Analysis	211	
15.	Summary Analysis of the Global IVD High-Growth Market by Geographic Region	213	
15.1	Summary Analysis of the Global IVD Market	213	
15.2	Summary Analysis of the Global IVD High-Growth Market by Geographic Region	216	
15.3	U.S.: Summary Analysis of the IVD High-Growth Market	217	
15.3.1	U.S.: Summary of IVD High-Growth Market	218	
15.3.2	Cardiac Markers	220	
15.4	Europe: Summary Analysis of the IVD High-Growth Market	223	
15.4.1	Summary of IVD High-Growth Market Europe	227	
15.5	Brazil: Summary Analysis of the IVD High-Growth Market	230	
15.5.1	Summary of IVD High-Growth Market Brazil	231	
15.6	Russia: Summary Analysis of the IVD High-Growth Market	233	
15.6.1	Summary of IVD High-Growth Market Russia	234	
15.7	India: Summary Analysis of the IVD High-Growth Market	236	
15.7.1	Summary of IVD High-Growth Market India	243	
15.8	China: Summary Analysis of the IVD High-Growth Market	245	
15.8.1	Summary of IVD High-Growth Market China	261	
15.9	South-East Asia and Japan: Summary Analysis of the IVD High-Growth Market	263	
15.9.1	Japan	264	
15.9.2	South Korea	267	
15.9.3	Rapid Growth Market of IVD HIV/AIDS Testing in Other Asia	269	
15.9.4	Summary of IVD High-Growth Market Other Asia	271	
16.	Clinical Laboratory Genomics	273	
16.1	Introduction	273	
16.2	Clinical Laboratory Genomics Testing	274	
16.3	Developments in Clinical Laboratory Genomics	275	
16.3.1	Nucleic Acid Amplification Techniques	275	

16.3.2	Chromosome Imaging	276	
16.3.3	Genomics Technologies	276	
16.3.4	Proteomics Technology	277	
16.3.5	Current Pharmacogenomic Tests	277	
16.3.6	Future Pharmacogenomic Testing	278	
17.	Cellular Imaging Cytopathology and Histopathology		280
17.1	Segment Overview	280	
17.2	The Market	280	
17.3	Market Drivers	282	
17.4	Market Restraints	282	
17.5	Cytology and Histology Technology Platforms	282	
17.5.1	Cytology Screening Procedures and Pap Smear Technology		283
17.5.2	Histology	288	
17.5.3	Market Drivers	290	
17.5.4	ISH Staining	290	
17.5.5	Special-Stains Staining	290	
17.6	Third-Party Reimbursement	290	
17.7	Competition	291	
18.	High-Growth Testing Diagnostic Trends	295	
18.1	Genetic Testing	295	
18.2	Quality Measures	295	
18.3	Moderators of Growth	295	
18.3.1	Diagnostics and the Aging Population	295	
18.3.2	Individualized Medicine	295	
18.3.3	Genetic Testing	295	
18.4	Workforce Issues	297	
18.5	Reimbursement	297	
18.5.1	Cardiovascular	298	
18.5.2	Screening for Diabetes	299	
18.5.3	CPT Test Codes and Payment Amounts	299	
18.6	Rapid Near-Patient Testing in Hospitals	302	
18.7	Satellite Facilities	302	
18.8	Regionalization of Laboratory Care	303	
18.9	Requirements for High-Growth Testing	304	
18.10	Clinical Laboratory Improvement Act (CLIA)	305	
19.	Important Technology Trends	308	
20.	Molecular Diagnostics a Major Diagnostic Technological Advance	311	
20.1	Polymerase Chain Reaction (PCR)-based Molecular Diagnostics	312	
20.2	Micrarray Technologies and Molecular Diagnostics	313	
20.3	Isothermal Amplification Technologies and Molecular Diagnostics	314	
20.4	Miniaturization Technologies and Molecular Diagnostics (Biochips and Lab on a Chip)		315
21.	Technology Platform Innovations in POCT	317	
21.1	Latest POCT Technological Platforms	317	
21.1.1	Device Miniaturization and Microfluidic Technologies	317	
21.1.2	Minimally Invasive and Non-invasive POCT Technologies	317	
21.1.3	Advances in Wireless Technologies	318	
21.1.4	Automation of POCT	318	
21.1.5	Developments in New Genomic Technologies (Genotyping, Haplotyping and Sequencing Technologies)	318	
21.1.6	Advances in Informatics Technologies	320	

21.1.7	Pharmacogenetic Testing	321	
21.1.8	Multi Assay Technologies in POCT	321	
21.2	Developments in Key Technologies	321	
21.2.1	Medical and Biological Sensors and Sensor Systems	321	
21.2.2	Recent Biosensor Product Introductions and Latest Innovative Developments	323	
21.2.2.1	Nanoscale Sensors for the Detection of Cancer Biomarkers	323	
21.2.2.2	ForteBio Introduces Dip and Read Protein G Biosensor for Octet Instruments	323	
21.2.2.3	ForteBio Launches New Octet RED96 System and Dip and Read Protein L Biosensor	323	
21.2.2.4	AgaMatrix Europe Limited Introduces the New Jazz Blood Glucose Meter in the U.K.	324	
21.2.2.5	STMicroelectronics to Manufacture Worlds Smallest Biosensors	324	
21.2.2.6	Universal Biosensors Advances Point of Care Molecular Diagnostic Opportunity	324	
21.2.2.7	Clinitek Advantus—A Semi Automated Urine Analyzer for Point of Care Testing	324	
21.2.2.8	The NOVA 16 STAT Chemistry Analyzer Offers the First All-Electrode-based Seven Test Chemistry Profile	324	
21.3	Sensor Systems for Diagnostic Applications	326	
21.4	Nanogen (The ELITech Group) Third Generation Point of Care Analyzer	329	
21.5	Philips Development of Magnotech Technology	329	
21.6	Quidel Corporation MChip, AVR Chip and F Chip	329	
21.7	Sanofi-Aventis	330	
22.	Data Management and Connectivity	331	
22.1	Wireless LANs	331	
22.2	Connectivity Platforms	334	
22.2.1	DataLink Data Management System	334	
22.2.2	RALS-Plus	335	
22.2.2.1	International Technidyne Corporation HEMOCHRON Signature Elite	337	
22.2.2.2	Siemens Diagnostics Rapidpoint Coag	337	
22.2.2.3	Radiometer	337	
22.2.2.4	HemoCue's DM Hemoglobin	337	
22.2.2.5	Roche Diagnostics	337	
22.2.3	BD.id	338	
22.2.4	Medical Implant Communications Service (MICS)	338	
22.2.5	Conworx Technology	338	
22.2.6	Lab Data Systems	339	
22.2.7	Medasys	339	
22.2.8	NoemaLife	339	
22.3	Advantages of POCT Connectivity	340	
22.3.1	Cost Benefit of POCT and IT Connectivity	340	
22.3.2	Hospital Network Issues	340	
22.4	POCT Analyzer Connectivity Software Solutions	341	
22.5	POCT2-P	343	
23.	Biochips for Clinical Applications	344	
23.1	Roche AmpliChip	352	
23.2	Amersham CodeLink	354	
23.3	Breast Cancer DNA Chips	354	
23.4	Osmetech eSensor	354	
23.5	Affymetrix GeneChip System 3000Dx v.2	355	
23.6	Caliper and Cepheid	355	
23.7	Agilent Technologies 2100 Lab-on-a-Chip	355	
24.	Company Profiles	357	
24.1	Abaxis, Inc.	357	
24.2	Abbott Laboratories	359	
24.3	Accurex Biomedical, Pvt. Ltd.	361	

24.4	Adeza Biomedical Corporation (Hologic)	361
24.5	Agilent Technologies, Inc.	361
24.6	Alere, Inc.	363
24.7	Ambri Ltd.	365
24.8	American Bio Medica Corp.	365
24.9	Ani Biotech	367
24.10	Applied Spectral Imaging	368
24.11	Avitar, Inc.	369
24.12	Axis-Shield	370
24.13	Bayer Corporation	371
24.14	Beckman Coulter	372
24.15	Becton Dickinson	375
24.16	Biomerica	376
24.17	Bio-Rad, Inc.	377
24.18	Calypte Biomedical Corporation	378
24.19	Chembio Diagnostics, Inc.	379
24.20	Cozart Bioscience	380
24.21	Denka Seiken Co., Ltd.	380
24.22	diaDexus, LLC	381
24.23	Enterix, Inc. (Subsidiary of Quest Diagnostics)	382
24.24	EY Laboratories, Inc.	382
24.25	Genetix	383
24.26	Genzyme Diagnostics	384
24.27	Hologic, Inc.	384
24.28	Instrumentation Laboratory (IL)/Werfen Group	386
24.29	Jiangnan Biotech	386
24.30	Johnson & Johnson	387
24.31	Kyowa Medex Co., Ltd.	388
24.32	LifeAssays AB	388
24.33	LifeScan	389
24.34	Matritech	389
24.35	A Menarini Diagnostics	390
24.36	Meretek Diagnostics Group	390
24.37	Meridian Bioscience	391
24.38	Medix Biochemica	393
24.39	Myriad Genetics	393
24.40	NOVA Biomedical	395
24.41	OraSure	396
24.42	Pheromone Sciences	398
24.43	Polymedco	399
24.44	Polymer Technology Systems, Inc.	400
24.45	QIAGEN	400
24.46	Quest Diagnostics, Inc.	401
24.47	Quidel	402
24.48	Radiometer Medical	406
24.49	Roche Diagnostics	409
24.50	Shanghai Siic Kehua Biotech Co., Ltd. (Kehua Biotech)	412
24.51	Shionogi & Co.	412
24.52	Siemens	412
24.53	Spectral Diagnostics, Inc.	413
24.54	Trinity Biotech, Plc	413
24.55	Väsamed, Inc.	416

INDEX OF FIGURES

Figure 1.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2011	18
Figure 1.2: Top 13 Country IVD Testing Markets, 2011	19
Figure 1.3: Company Market Share for IVD Testing Markets, 2011	19
Figure 3.1: Evolution of HBV Markers in Acute and Chronic Infection	36
Figure 6.1: Global Incidence of Malaria	96
Figure 6.2: Mode of Action of Common Malaria RDT Format	99
Figure 6.3: FIND Pipeline for TB Diagnostics	109
Figure 15.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2011	214
Figure 15.2: Top 13 Country IVD Testing Markets, 2011	215
Figure 15.3: Company Market Share for IVD Testing Markets, 2011	215
Figure 15.4: Indian Diagnostics Market Segments, 2011	240
Figure 15.5: The Chinese Healthcare System	246
Figure 17.1: Worldwide Incidence Rates of Cervical Cancer Per 100,000 Females, 2011	284

INDEX OF TABLES

Table 1.1: Emerging Technology Platforms Driving High-Growth Diagnostics Market Segments	14
Table 1.2: Market Trends in the High-Growth Diagnostics Space	16
Table 1.3: Worldwide Geographic Distribution of Total IVD Testing Market, 2011	18
Table 1.4: Top 13 Country IVD Testing Markets, 2011	18
Table 1.5: Company Market Share for IVD Testing Markets, 2011	19
Table 1.6: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018	20
Table 1.7: Global IVD High-Growth Markets Revenues by Market Segment, 2008-2018	21
Table 1.8: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018	21
Table 1.9: Global IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018	22
Table 3.1: Serological Diagnosis of Hepatitis B Virus Infections	32
Table 3.2: Lower Detection Limits of HBV DNA Assays	33
Table 3.3: Summary of Selected Suppliers of Hepatitis B Virus (HBV) Diagnostic Products by Technology	37
Table 3.4: Global Revenue Forecasts for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Diagnostic Testing, 2008-2018	39
Table 3.5: Global Revenue Forecasts for Hepatitis B Virus (HBV) Diagnostic Testing, 2008-2018	40
Table 3.6: Efficiency of Available HCV Screening Tests	44
Table 3.7: Recommendations for Diagnostic Testing for Hepatitis C	45
Table 3.8: Hepatitis C Statistics	46
Table 3.9: Novartis Diagnostics Clinical Diagnostic Products Test for the Detection of HCV	47
Table 3.10: Global Revenue Forecasts for Hepatitis C Virus (HCV) Diagnostic Testing, 2008-2018	49
Table 4.1: HPV Risk Factors	50
Table 4.2: HPV and Cervical Carcinoma	51
Table 4.3: Key statistics on Cervical Cancer in the World, 2011	52
Table 4.4: Reflex HPV Testing with Cytology	57
Table 4.5: Predictability of HPV Test by Abnormal Pap Smear Type	57
Table 4.6: Long-Term Trends in HPV Testing	58
Table 4.7: Global Revenue Forecasts for Human Papillomavirus (HPV) Diagnostic Testing, 2008-2018	58
Table 5.1: Global HIV Statistics, 2009	62
Table 5.2: Antiretroviral Therapy (ART) Coverage, 2008	63
Table 5.3: Estimated Number of HIV Infection, 2009	64
Table 5.4: Estimated Number of AIDS Infection, 2009	64
Table 5.5: Drivers of Demand for HIV Diagnostic Testing	65
Table 5.6: NAT HIV Monitoring Market: Market Drivers Ranked in Order of Impact	66
Table 5.7: Drivers of Demand for HIV Diagnostic Testing	66
Table 5.8: NAT HIV Monitoring Market: Market Restraints Ranked in Order of Impact	66
Table 5.9: Selected POC Infectious Disease Testing Devices, 2011	70

Table 5.10: Global Revenue Forecasts for HIV and AIDS Diagnostic Testing, 2008-2018	72
Table 5.11: Competitive Factors Related to HIV Tests	74
Table 6.1: Rapid Strep Tests on the Market	84
Table 6.2: Rapid Tests for Chlamydia	88
Table 6.3: Rapid Tests for Gonorrhea	92
Table 6.4: Commercially-available Rapid Tests for Malaria	102
Table 6.5: Estimated TB Incidence, Prevalence and Mortality, 2009	105
Table 6.6: FIND Partners	110
Table 6.7: Global Market Potential for TB Diagnostic Testing, 2000-2010	112
Table 6.8: MRSA Diagnostics Currently on the Market	114
Table 6.9: Global Revenue Infectious Disease Revenue Analysis, 2008-2018	115
Table 7.1: Medication Chart for Cardiovascular Disease	120
Table 7.2: BNP Clinical Characteristics	124
Table 7.3: Cardiovascular Risk Classification by CRP Level	129
Table 7.4: Clinical Characteristics of D-dimer	129
Table 7.5: Global Revenue Forecasts for Cardiac Marker Testing, 2008-2018	138
Table 8.1: Genetic Testing: Consequences and Challenges	143
Table 8.2: CF Carrier Risk by Ethnic Group	143
Table 8.3: Reasons for CF Testing	144
Table 8.4: CF Gene Detection Rates Vary by Ethnic Background	145
Table 8.5: Global Market for CF Diagnostic Testing, 2008-2018	146
Table 8.6: U.S. Market for CF Diagnostic Testing, 2008-2018	146
Table 8.7: Commercial CF Screening Products	147
Table 8.8: Emerging CF Screening Products	147
Table 9.1: The Fertility Testing Market in the U.S., 2008-2018	149
Table 10.1: Estimated Numbers of New Cases for Selected Cancers in the U.S., 2012	154
Table 10.2: Five-Year Disease-free Survival by Stage at Diagnosis	155
Table 10.3: TPA Marker Sensitivity	164
Table 10.4: INFINITI Applications	178
Table 10.5: Global Revenue Forecasts for Cancer Marker Testing, 2008-2018	179
Table 11.1: Drug Testing Needs Tier I for Rapid Serum POCT in the Emergency Department	185
Table 11.2: Stat Urine Testing Drug Recommendations	186
Table 11.3: Selected POC Substance/Drug Abuse Testing Devices, 2011	190
Table 11.4: Selected POC Substance/Drug Abuse Testing Devices, OraSure, 2011	198
Table 11.5: Selected Target Substances and Drugs, 2011	199
Table 11.6: Global Revenue Forecasts for Substance Abuse Testing, 2008-2018	203
Table 12.1: Global Revenue Forecasts for Vitamin D Testing, 2008-2018	208
Table 14.1: Global Revenue Forecasts for Companion Diagnostics, 2008-2018	212
Table 15.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2011	213
Table 15.2: Top 13 Country IVD Testing Markets, 2011	214
Table 15.3: Company Market Share for IVD Testing Markets, 2011	215
Table 15.4: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018	216
Table 15.5: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018	216
Table 15.6: Global IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018	217
Table 15.7: Summary of IVD High-Growth Market U.S., 2011	218
Table 15.8: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing U.S., 2008-2018	218
Table 15.9: U.S. Individual IVD High-Growth Markets Revenue Forecast, 2008-2018	219
Table 15.10: U.S. Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018	219
Table 15.11: Specific Cardiac Markers	220
Table 15.12: Cardiac Markers after Onset of Myocardial Infarction	221
Table 15.13: U.S. Cardiac Marker Revenue Forecasts, 2008-2018	223
Table 15.14: Market Share of Cardiac Marker Segment	223
Table 15.15: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Europe,	

2008-2018	227	
Table 15.16: Europe: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018		228
Table 15.17: Europe: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018	228	
Table 15.18: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Brazil, 2008-2018	232	
Table 15.19: Brazil: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018		232
Table 15.20: Brazil: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018	233	
Table 15.21: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Russia, 2008-2018	234	
Table 15.22: Russia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018		235
Table 15.23: Russia: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018	235	
Table 15.24: Overview of Healthcare in India	237	
Table 15.25: Population Projections India	239	
Table 15.26: Statistical Healthcare Data India	239	
Table 15.27: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing India, 2008-2018	244	
Table 15.28: India: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018		244
Table 15.29: India: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018	245	
Table 15.30: Number of Healthcare Institutions According to Ownership China, 2010	247	
Table 15.31: Total Number of Hospitals by Ranking China, 2010	248	
Table 15.32: Disease Burden in China: Urban and Rural	249	
Table 15.33: China Biotech Reagents Market	257	
Table 15.34: Biotechnology Projects Between China and the West	258	
Table 15.35: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing China, 2008-2018	262	
Table 15.36: China: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018		262
Table 15.37: China: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018	263	
Table 15.38: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Other Asia, 2008-2018	271	
Table 15.39: Other Asia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018		272
Table 15.40: Other Asia: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018	272	
Table 17.1: Estimated Cervical Cancer Cases/Deaths Worldwide, 2011	286	
Table 17.2: Medicare Reimbursement for Cervical Pathology Procedures	290	
Table 18.1: New CPT Test Codes Introduced in 2008	301	
Table 19.1: Employment of Clinical Laboratory Workers, 2006-2016	309	
Table 21.1: Common Genotype Techniques	319	
Table 22.1: Applications for Wireless LAN Technology	331	
Table 22.2: Customized Reports Must Support CAP and JCAHO Requirements	335	
Table 22.3: RALS-Plus Point of Care Market Share	336	
Table 22.4: Applications of RALS Connectivity with POCT Devices	336	
Table 23.1: Biochip Revenues and Growth Rates by Application, 2003 and 2007	344	
Table 23.2: Total Biochip Market: Worldwide Revenue Forecasts, 2008-2018	349	
Table 23.3: Total Biochip Market: U.S. Revenue Forecasts, 2008-2018	349	
Table 24.1: Abaxis, Inc. Financial Figures—Net Sales by Business Sector, 2008-2010	358	
Table 24.2: Abaxis, Inc. Financial Figures—Net Sales by Geographic Region, 2008-2010	359	
Table 24.3: Abbott Laboratories Financial Figures—Net Sales by Business Sector, 2008-2010	360	
Table 24.4: Abbott Laboratories Financial Figures—Net Sales by Geographic Region, 2008-2010	360	
Table 24.5: Alere, Inc. Financial Figures—Net Sales by Business Sector, 2008-2010	364	
Table 24.6: Alere, Inc. Financial Figures—Net Sales by Geographic Region, 2008-2010	365	

Table 24.7: Bayer AG Financial Figures—Net Sales by Business Sector, 2008-2010	372
Table 24.8: Bayer AG Financial Figures—Net Sales by Geographic Region, 2008-2010	372
Table 24.9: Bio-Rad Laboratories, Inc. Financial Figures—Net Sales by Business Sector, 2008-2010	377
Table 24.10: Bio-Rad Laboratories, Inc. Financial Figures—Net Sales by Geographic Region, 2008-2010	378
Table 24.11: Johnson & Johnson Financial Figures—Net Sales by Major Medical and Diagnostics Businesses, 2008-2010	388
Table 24.12: Quidel Product Sales Distribution and Sales, 2009 and 2010	403
Table 24.13: Danaher Corporation Financial Figures—Net Sales by Business Sector, 2008-2010	407
Table 24.14: Danaher Corporation Financial Figures—Net Sales by Geographic Region, 2008-2010	407
Table 24.15: Roche Group Financial Figures—Net Sales by Business Sector, 2008-2010	411
Table 24.16: Roche Group Financial Figures—Net Sales by Geographic Region, 2009 and 2010	411
Table 24.17: Roche Group Financial Figures—Net Sales by Sub-Division, 2008-2010	411

SAMPLE

1. Overview

1.1 Statement of Report

The purpose of this report is to describe the specific market segment of the *in vitro* diagnostics market called high-growth diagnostic testing. It examines the clinical measurement devices and their reagents and supplies as utilized in hospitals, clinics and doctor's offices. Each diagnostic segment described in this report offers an outstanding opportunity for strong market growth over the next five years. Our analysis is arranged to provide the reader with an overview of the outstanding diagnostic test growth market segments that are poised for unusual advances in sales and earnings as the diagnostic market becomes an increasingly important segment of the health delivery system. Each high-growth market segment is accompanied by analysis and forecasts by product type and application.

This analysis provides an overview of the newest growth areas of the diagnostic testing market, including the latest information regarding new products and important industry trends. Forecasts of the market and analyses of products in the worldwide diagnostics market will provide a basis for understanding the significance of new developments and future possibilities within the diagnostic testing segment.

The principal objectives of this review are to:

- Identify key technology drivers through a comprehensive look at various platform technologies for high-growth segments of the diagnostic testing markets.
- Obtain a complete understanding of the chief high-growth diagnostic test predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic value, from their basic principles to their applications.
- Discover feasible market opportunities via an identification of high-growth applications in different diagnostic testing areas, with a focus on the biggest and fastest expanding markets for diseases.
- Focus on global industry development through an in-depth analysis of the major world markets for high-growth diagnostic testing, including forecasts for growth.
- Project and forecast the future of the IVD market. Market figures regarding the current value of the high-growth testing market are taken from the most recent available data of the global diagnostic industry.

This report provides:

- An improved understanding of the current state and future of the most exciting high-growth diagnostic testing market segments.
- The latest information on the leading companies engaged in R&D and diagnostic testing products in the pipeline.
- The analyst's perspective of recent diagnostic test developments, and revelations on how these influence selected markets.
- Knowledge of the diagnostic testing market as an area of growth, research and investment.

The following categories of diagnostic testing segments are covered herein:

- Hepatitis testing.
- Cardiac monitoring.
- Cytogenetic testing.
- Fertility testing.
- Laboratory genomics.
- Glycosylated hemoglobin and glucose monitoring.
- Cancer marker testing.
- Human papillomavirus (HPV).
- Biochips for clinical applications.
- HIV.
- Cellular imaging cytopathology and histopathology.
- Infectious disease testing.

Analyses include the use of charts and graphs measuring product growth and trends within the marketplace. In addition, a discussion of research in the illness provides the reader with a deeper understanding of possibilities for future diagnosis and avenues for possible research and development budgets. Company-specific information—including product pipeline status, and research and development trends—is provided throughout the report. Additionally, this analysis will:

- Assess the high-growth diagnostic testing market drivers and bottlenecks, from the perspective of the diagnostics industry, as well as medical and scientific communities.
- Discuss the potential benefits provided by the high-growth diagnostic testing market to various sectors of the medical and scientific community.
- Establish the current total market size and future growth of the high-growth diagnostic testing market, and analyze the current size and growth of individual segments.
- Provide current and forecasted market shares by company.
- Discuss business opportunities in the high-growth diagnostic testing segment.
- Provide strategic recommendations for exceptional near-term business opportunities.
- Assess current commercial uses of the high-growth diagnostic testing market.

We answer the following questions in this report:

- What are the near-term business opportunities in the high-growth diagnostic testing market?
- What are the current and forecasted sizes of the high-growth diagnostic testing market?
- What are the business models currently used by companies in the high-growth diagnostic testing market?
- How will diagnostic manufacturers, researchers, physicians, patients and payers influence the high-growth diagnostic testing market?
- What are the drivers and bottlenecks influencing the high-growth diagnostic testing market?
- What are the technologies used in high-growth diagnostic testing?
- Who holds proprietary rights to the high-growth diagnostic testing market technology?
- What are current applications of this technology?
- What regulatory processes must the high-growth diagnostic technologies undergo in the United States, Japan, China and Europe?
- How will new high-growth diagnostic testing technologies change treatment and payment paradigms?
- How will high-growth diagnostic testing technologies reduce adverse drug reactions and decrease total patient care costs?
- How will high-growth diagnostic testing technologies reduce healthcare expenditures?

1.2 Scope of This Report

The emphasis in this review is on those companies that are actively developing and marketing high-growth diagnostic testing technologies. The reader should consult other TriMark Publications reports at www.trimarkpublications.com for a detailed discussion of the important individual market segments which are related to the high-growth diagnostic testing technologies market, such as hepatitis testing, cardiac markers, cancer testing, infectious disease markers and other new diagnostic methods.

This analysis concentrates on high-growth testing market segments in important worldwide markets, such as the U.S., Japan, China and Europe, including Germany, the United Kingdom, and other countries of the European Union (E.U.). It focuses primarily on the hospital market and commercial laboratory segment, and, separately, on a description of the instruments, reagents and supplies marketed by major companies in this segment. The report discusses market size, growth rates, and market components, and five-year projections for each of the important high-growth tests.

1.3 Methodology

The author of this report holds a Ph.D. in biochemistry from the University of Minnesota and has had post-doctoral experience at the University of Connecticut School of Medicine. He has taught at Quinnipiac University and the Tufts School of Medicine, and has been a senior scientist at Pfizer Pharmaceutical Laboratories in drug development. He also has many decades of experience in science writing and as a medical industry analyst. He has over 30 years of experience in laboratory testing and instrument and reagent development technology as a licensed clinical laboratory director, as well as extensive experience in senior level management positions in biotech and medical service companies. The editor of this report is a Ph.D. in biochemistry from the University of Liverpool with many decades of experience in science writing and as a medical industry analyst.

Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additional sources of information include non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities such as the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that it publishes annually. TriMark extracts relevant data and analytics from its research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

TriMark Publications Report Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly available databases, proprietary databases, direct meetings and personal interviews with key personnel.
- Formulating a study outline with the assigned writer, including important items:
 - Market and product segment grouping and evaluating their relative significance.
 - Key competitors' evaluations including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
 - End-user research to evaluate analytical significance in market estimation.

- Supply chain research and analysis to identify any factors affecting the market.
- New technology platforms and cutting edge applications.
- Identifying the key technology and market trends that drive or affect these markets. Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Launching a combination of primary research activities including two levels of questionnaires, executive-direct focused, company-specific, and region-specific communications to qualified and experienced senior executives worldwide.
- Completing a confirmatory primary research assessment of the report's findings with the assistance of Expert Panel Partners from the industry being analyzed.

1.4 Executive Summary

The high-growth diagnostic products segments are poised for a major new phase of growth fueled by the availability of new technology coming out of the point of care segment and human genome research; and also the higher interest of individual patients and general healthcare consumers to take charge of their own health status. Continuous improvements in technology are resulting in a growing number of new *in vitro* diagnostic tests that combine high levels of accuracy with rapid, easy-to-use product formats. The combination of the new molecular diagnostic technology platforms and traditional PCR will provide customers with a highly sensitive, accurate and rapid solution that is even more robust than either of them alone. These innovative combinations will provide the rich environment for diagnostic tests that grow more than █% per year in net sales dollars.

Many high-growth *in vitro* diagnostic products and services are specifically targeted at markets outside of the traditional hospital or clinical laboratory such as the point of care setting or genetic screening. Competition in the development and marketing of high-growth diagnostic products is intense, and diagnostic technologies have been subject to rapid change. We estimate that the competitive factors determining success in the diagnostic market include convenience, privacy, price and product performance as well as the distribution, advertising, promotion and brand name recognition of the marketer.

Table 1.1: Emerging Technology Platforms Driving High-Growth Diagnostics Market Segments

-
- Polymerase Chain Reaction (PCR).
 - SYBR Green (Non-probe System).
 - MultiCode RTx System.
 - Taq-Man™ (Probe System).
 - HybProbe (Probe System).
 - Molecular Beacons (Probe System).
 - Branched DNA (bDNA).
 - Transcription Mediated Amplification (TMA).
 - Invader.
 - MultiCode® PLx.
 - Tag-It®.
 - Signature™.
 - Other Real-time PCR Instruments.
-

Source: Biotechnology Associates

Expiration of basic PCR patents in [REDACTED] opened additional opportunities for new diagnostic test markets. Compared to traditional methods, molecular diagnostics offers better performance, shorter testing times and objective results that do not require interpretation by highly-trained technologists. Most of all, clinicians are now able to provide patients and the community with more consistent, affordable and higher-quality healthcare. Expertise in nucleic acid testing (NAT) products and the associated technology platforms has enabled a number of companies to enter this high-growth segment and to obtain U.S. Food and Drug Administration (FDA) approvals for products that detect a wide variety of infectious microorganisms.

TriMark believes that markets will continue to develop for new applications for NAT technology, both in clinical and non-clinical fields. Among clinical fields, we believe NAT technology will be used in new applications, such as genetic predisposition testing and pharmacogenomics, which involves the study of the relationship between nucleic acid sequence variations in an individual's genome and the individual's response to a particular drug. We expect that nucleic acid assays will be used in the field of pharmacogenomics to screen patients prior to administering new drugs. Genetic testing to identify individuals at risk of certain diseases and pathological syndromes is emerging as an additional market for NAT technology. Nucleic acid-based testing for SNPs and other genetic anomalies can be used to determine an individual's predisposition to such conditions as thrombosis or blood clotting.

We see significant opportunities to grow the high-growth diagnostic testing business outside of the U.S. For example, we expect that the enhanced organization will play a critical role in the further commercialization of high-growth diagnostic tests like HPV, tests for cervical cancer screening, urine strip testing in less developed regions, infectious disease testing and hepatitis screening. The high-growth *in vitro* diagnostic testing market segment is characterized by growth frequently above [REDACTED] % per year, and occasionally much more. More established testing market segments like hepatitis, HIV or glycohemoglobin are in the former range of growth. Newer segments like laboratory genomics and biochips are in the [REDACTED] % range of growth, but start from a low base in the \$[REDACTED] per year range, compared to the nearly \$[REDACTED] estimate for more mature testing segments like hepatitis. The major players using the following strategies are pursuing growth in the high-growth sector:

- Improving profit margins through improved product pricing and operational efficiencies.
- Securing a stronger new product pipeline from internal research and development.
- Pursuing licensing and acquisitions opportunities, when financially and strategically attractive.
- Launching diagnostic test business under brand by leveraging marketing and distributing strength in the U.S., maximizing worldwide sales through current and newly identified sales channels in Europe and the rest of world.
- Launching a new and improved CLIA-waived test worldwide.
- Launching rapid diagnostic tests on a worldwide basis in conjunction with a development partner such as a pharmaceutical company.
- Expanding development and marketing collaborations with large pharmaceutical and other healthcare companies.
- Identifying business development opportunities in the form of product or company acquisitions to enhance product portfolio and further leverage distribution channels worldwide.
- Expanding international sales through external alliances, collaborations and sales focus.

TriMark believes that significant market potential exists for rapid diagnostics with novel applications that are capable of precise quantitative measurement of single or multiple analytes. Rapid, point of care testing is optimal to significantly improve patient care and reduce healthcare costs, especially for acute conditions. However, diagnostic needs and objectives vary from hospital to hospital. Therefore, most diagnostic reagent manufacturers have made their tests available on a centralized automated testing platform in addition to their own existing technology platforms.

Table 1.2: Market Trends in the High-Growth Diagnostics Space

-
- Tests based upon molecular diagnostic (nucleic acid) technology platforms.
 - Move toward marketing rapid point of care test kits.
 - Tests developed as CLIA-waived tests.
 - Cost per test less of an issue with high demand diagnostic tests.
 - Coupling the diagnostic test with high profile diseases, *e.g.*, ovarian or breast cancer.
 - Move toward bringing complicated tests into a single expert lab.
 - Move for CLIA regulatory oversight using expert labs, rather than FDA using diagnostic kits.
 - Move away from central lab “big iron” chemistry analyzers.
 - Focus on improving patient outcomes with diagnostic tests.
 - Move to reduce expertise needed to run tests because of shortage of trained personnel.
 - More diagnostic start-ups to develop tests with high growth potential.
 - Increased M&As as larger players acquire exciting new test technology.
-

Source: Biotechnology Associates

Rapid identification of biological agents is critical to national defense, for example, the application of technology to the detection of biological agents in the water supply. There is currently a need for optimizing a platform for specific use as a field-deployable system to enable biodefense first responders, such as fire and police departments, to rapidly and more accurately detect signature nucleic acid sequences of known biological pathogens (*e.g.*, anthrax and plague). Public attention to agricultural biotechnology continues to grow. Several companies are developing a diagnostic tool to detect genetically modified organisms (GMOs) and address the need to rapidly identify biologic contamination. Approximately \$[REDACTED] was spent on genomic and proteomic research in [REDACTED], and this figure is projected to grow by at least [REDACTED]% each year for the next five years. The underlying technology must be applicable to both disease and population-driven genomics and are best developed through corporate partnerships.

The demand for the latest tests and technology is expanding. More and more hospital labs are consolidating and seeking to expand their test menus, and to keep more tests on-site. At the same time, larger independent reference labs like Quest Diagnostics and LabCorp are seeking to stay on the cutting edge of esoteric testing and are making major investments in research and development to keep pace. We have selected [REDACTED] test categories that we believe constitute most of the total high-growth *in vitro* diagnostic testing market:

- Hepatitis testing.
- Cardiac markers.
- Cytogenetic testing.
- Fertility testing.
- Genomics testing.
- Glycosylated hemoglobin and glucose monitoring.
- Cancer testing.
- HPV.
- Biochips for clinical applications.
- HIV.
- Cellular imaging.
- Infectious disease testing.